神工股份(688233.SH)发布公告，公司股东温州晶励、旭捷投资因自身发展需要，拟通过上海证券交易 所交易系统以集中竞价、大宗交易方式减持公司股份合计不超过335.94万股(即不超过公司总股本的 1.98%)。 ...

证券代码：688233 证券简称：神工股份 公告编号：2025-044 锦州神工半导体股份有限公司 持股 5%以上股东的一致行动人 减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及一致行动人的基本情况 截至本公告披露日,锦州神工半导体股份有限公司（以下简称"公司"）股 东矽康半导体科技（上海）有限公司（以下简称"矽康半导体"）持有公司股份 35,550,301 股，占公司总股本的 20.87%；股东温州晶励企业管理合伙企业（有 限合伙）（以下简称"温州晶励"）持有公司股份 2,873,733 股，占公司总股本的 1.69%；股东宁波梅山保税港区旭捷投资管理合伙企业（有限合伙）（以下简称"旭 捷投资"）持有公司股份 485,701 股，占公司总股本的 0.29%。上述股东为一致 行动人，合计持有公司股份 38,909,735 股，占公司总股本的 22.85%。 上述股份均来源于公司首次公开发行前持有的股份，且已于 2023 年 2 月 21 日起解除限售并上市流通。 减持 ...

智通财经APP讯，神工股份(688233.SH)发布公告，公司股东温州晶励、旭捷投资因自身发展需要，拟 通过上海证券交易所交易系统以集中竞价、大宗交易方式减持公司股份合计不超过335.94万股(即不超 过公司总股本的1.98%)。 ...

人民财讯12月15日电，神工股份(688233)12月15日公告，公司股东温州晶励、旭捷投资因自身发展需 要，拟通过上海证券交易所交易系统以集中竞价、大宗交易方式减持公司股份合计不超过335.94万股 (即不超过公司总股本的1.98%)。 ...

每经AI快讯，12月15日，神工股份(688233.SH)公告称，公司股东温州晶励、旭捷投资因自身发展需 要，拟通过上海证券交易所交易系统以集中竞价、大宗交易方式减持公司股份合计不超过335.94万股， 即不超过公司总股本的1.98%。 ...

神工股份公告，持股5%以上股东矽康半导体科技（上海）有限公司一致行动人温州晶励企业管理合伙 企业（有限合伙）及宁波梅山保税港区旭捷投资管理合伙企业（有限合伙）计划通过集中竞价和大宗交 易方式合计减持不超过335.94万股，占公司总股本的1.98%。具体而言，温州晶励拟在2026年1月8日至 2026年4月7日期间减持不超过287.37万股，占1.69%；旭捷投资拟减持不超过48.57万股，占0.29%。此 次减持系因自身资金需求，不会对公司治理结构及持续经营产生重大影响。 ...

Core Insights - The article highlights the acceleration of business development (BD) activities in the medical device sector from September to November 2025, with a total of 58 transactions identified across various subfields, including cardiovascular, nuclear medicine, and AI-enabled devices [2][3][4]. Group 1: Mergers and Acquisitions - Mergers and acquisitions have become a prominent form of BD, with companies leveraging capital control and product integration for rapid market positioning [7][8]. - Notable acquisitions include HeartLink's $680 million all-stock acquisition of Micro-Invasive Cardiology, enhancing its structural heart disease and rhythm management capabilities [7]. - Hua'an Zhonghui's acquisition of Bangni Medical marks its entry into the absorbable suture market, indicating a shift in surgical instrument competition towards material innovation [7]. Group 2: Strategic Collaborations - Strategic partnerships have been formed during the China International Import Expo, with companies like Shanghai Pharmaceuticals collaborating with international giants such as Boston Scientific and Medtronic to enhance their supply chain and academic promotion systems [7][8]. - The collaboration between GuoYao Medical and BDI Medical aims to deepen market penetration in the biomedicine and medical device sectors, focusing on compliance and distribution channel construction [13]. Group 3: Cross-Border Cooperation - Cross-border transactions have become more active, with foreign companies establishing local R&D and production systems in China, while domestic firms are exporting their solutions globally [9][10]. - The partnership between Trasis SA and Beijing Pait Biotechnology to establish a joint venture reflects a trend towards localized production and phased integration in the Chinese market [12]. Group 4: Ecosystem Building and Channel Expansion - The integration of supply chains and ecosystem building is a key theme, with companies focusing on collaborative agreements to enhance their market presence [11][15]. - The collaboration between Baxter and Neusoft Medical aims to create a comprehensive surgical solution by integrating their respective technologies [12]. Group 5: AI and Smart Healthcare - AI and data-driven approaches are becoming central to BD collaborations, with companies increasingly focusing on smart healthcare solutions [16][17]. - The partnership between Kefu Medical and Tencent Cloud to develop AI-powered hearing aids exemplifies the trend of integrating technology into healthcare products [21]. Group 6: Research and Diagnostic Synergy - The frequency of research-oriented collaborations is rising, indicating a shift from manufacturing-driven to research-driven industry dynamics [18][19]. - The collaboration between BGI and Infinera to enhance clinical applications of sequencing technology highlights the growing importance of research in driving innovation in the medical device sector [21].

Group 1 - A total of 7 stocks from the Sci-Tech Innovation Board (STAR Market) experienced block trading on December 11, with a cumulative transaction amount of 224 million yuan [1] - The stock with the highest transaction amount was Hu Silicon Industry, with 2 block trades totaling 4.2 million shares and a transaction amount of 88.284 million yuan [1] - Other notable stocks in terms of transaction amounts included Jintian Titanium Industry and Shengkong Co., with transaction amounts of 55.56 million yuan and 33.3871 million yuan respectively [1] Group 2 - All stocks involved in block trading on this day were sold at a discount, with the highest discount rates observed in Tongyuan Environment, Shengnuo Biology, and Ao Precision Medical, at 23.67%, 8.69%, and 2.02% respectively [1] - The STAR 50 Index fell by 1.55% on the same day, with 115 stocks rising, accounting for 19.33% of the total [1] - Among the stocks that underwent block trading, the average increase was 0.05%, with Tongyuan Environment and Jintian Titanium Industry showing the highest increases of 6.11% and 1.24% respectively [1] Group 3 - Institutional trading accounted for 4 transactions involving 3 stocks, with the highest buying amounts in Hu Silicon Industry, Jintian Titanium Industry, and Tongyuan Environment, at 42.04 million yuan, 18.54 million yuan, and 3.183 million yuan respectively [2] - The stocks with the highest net inflow of funds were Jintian Titanium Industry, Tongyuan Environment, and Ao Precision Medical, with net inflows of 8.3574 million yuan, 3.7699 million yuan, and 2.7902 million yuan respectively [2] - Conversely, Hu Silicon Industry, Xinlian Integration, and Shengnuo Biology experienced the highest net outflows, totaling 42.9021 million yuan, 22.0884 million yuan, and 9.8157 million yuan respectively [2]

12月11日神工股份大宗交易一览 神工股份12月11日大宗交易平台出现一笔成交，成交量52.69万股，成交金额3338.71万元，大宗交易成 交价为63.36元，相对今日收盘价折价0.85%。该笔交易的买方营业部为中信证券股份有限公司总部(非 营业场所)，卖方营业部为长江证券股份有限公司北京新源里证券营业部。 进一步统计，近3个月内该股累计发生6笔大宗交易，合计成交金额为1.93亿元。 证券时报·数据宝统计显示，神工股份今日收盘价为63.90元，下跌1.37%，日换手率为5.80%，成交额为 6.42亿元，全天主力资金净流出422.09万元，近5日该股累计上涨3.06%，近5日资金合计净流出1899.83 万元。 两融数据显示，该股最新融资余额为3.72亿元，近5日增加2923.48万元，增幅为8.53%。 据天眼查APP显示，锦州神工半导体股份有限公司成立于2013年07月24日，注册资本17030.5736万人民 币。（数据宝） | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | ...

| No 224 082 year 111 1274 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | 卖出营业部 | 是否为专场 | | 025-12-11 | 神工股份 | 688233 | 63.36 | 3338.71 | 52.69 | 去筒浸蒸馏臭型 | 美景香港露露酒 | Ka | 12月11日，神工股份大宗交易成交52.69万股，成交额3338.71万元，占当日总成交额的4.94%，成交价 63.36元，较市场收盘价63.9元折价0.85%。 ...